The therapeutic capacity of bone marrow MSC‐derived extracellular vesicles in Achilles tendon healing is passage‐dependent and indicated by specific glycans

The therapeutic potential of mesenchymal stem cell (MSC)‐derived extracellular vesicles (EVs) for various diseases and tissue repair is attracting attention. Here, EVs from conditioned medium of human bone marrow MSCs at passage 5 (P5) and passage 12 (P12) were analysed using mouse Achilles tendon rupture model and lectin microarray. P5 MSC‐EVs accelerated Achilles tendon healing compared with P12 MSC‐EVs. Fucose‐specific lectin TJA‐II was indicated as a glycan marker for therapeutic MSC‐EVs. The present study demonstrated that early passaged MSC‐EVs promote Achilles tendon healing compared with senescent MSC‐EVs. Glycans on MSC‐EVs might provide useful tools to establish a quality control and isolation system for therapeutic MSC‐EVs in regenerative medicine. The present study demonstrated that early passaged mesenchymal stem cell‐derived extracellular vesicles (P5 MSC‐EVs) promote Achilles tendon healing compared with senescent MSC‐EVs (P12 MSC‐EVs). Fucose‐specific lectin TJA‐II was indicated as a glycan marker for therapeutic MSC‐EVs. Glycans on MSC‐EVs might provide useful tools to establish a quality control and isolation system for therapeutic MSC‐EVs in regenerative medicine.